ALX 101

Drug Profile

ALX 101

Alternative Names: A-110; ALX-101; LXR agonist

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexar Therapeutics
  • Developer Ralexar Therapeutics
  • Class Skin disorder therapies
  • Mechanism of Action Liver X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 31 May 2017 Ralexar initiates enrolment in a phase IIb trial for Atopic dermatitis in USA
  • 26 Apr 2017 Ralexar Therapeutics initiates a phase IIb trial in Atopic dermatitis in USA (Topical) (NCT03175354)
  • 23 Nov 2015 Phase-II clinical trials in Atopic dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top